On 27 May 2008, the Commission received a notification of a proposed concentration by which the undertaking Nordic Capital (‘Nordic Capital’, Jersey) acquires control of the whole of the undertaking ConvaTec (‘ConvaTec’, USA), a wholly owned business unit of Bristol-Myers Squibb Co. (‘BMS’, USA), by way of purchase of shares and assets.

The business activities of the undertakings concerned are:
Nordic Capital: Nordic Capital is a group of private equity funds focusing primarily on investments in the Nordic region. Nordic Capital seeks to create value in its investments through committed ownership and by targeting strategic development and operational improvements.

ConvaTec: ConvaTec deal in the manufacture, marketing and sale of advanced wound care, ostomy and faecal incontinence products. ConvaTec is dedicated to bettering the lives of patients, their supporting caregivers and healthcare professionals with innovative, high quality products and product-related services for ostomy care, skin care and advanced wound care. This dedication and commitment to meeting customers’ needs has been our passion for over 25 years.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission. Observations must reach the Commission not later than the 13th June 2008 to:
European Commission
Directorate-General for Competition
Merger Registry
J-70
B-1049 Bruxelles/Brussel
or by fax ((32-2) 296 43 01 or 296 72 44)